Navigation Links
Data Released at an International Stem Cell Meeting Highlights Effectiveness of New Patient Education System Developed to Support Federal and State Guidelines on Cord Blood Education
Date:9/23/2009

BALTIMORE, Sept. 23 /PRNewswire/ -- Despite significant efforts by government agencies, consumer advocacy groups and industry to educate expecting parents about the medical significance of cord blood stem cells and the options for preserving them, three out of every four pregnant women still consider themselves only "minimally informed." However, data presented at an international meeting on stem cell science and policy found that a proprietary, web-based education system developed by Cord Blood Registry could be an effective and efficient method for improving awareness about all cord blood preservation options. In a survey of individuals who completed the education program, 93 percent indicated the program increased their knowledge and 95 percent indicated they were satisfied with the program overall.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090326/SF89756LOGO)

"The goal of this cord blood education program is to help physicians, and other labor and delivery specialists, provide expecting parents with scientifically-accurate information in a compelling format so they can make an informed choice about the options for preserving their newborn's cord blood stem cells," said Heather Brown, MS, CGC, vice president scientific & medical affairs at Cord Blood Registry. "This Web-based system offers many advantages in that it is accessible at any time of day, it's easily shared with spouses and other family members, and can provide documentation of the patient's education and informed choice, especially where public policy encourages or requires education."

The Institute of Medicine (IOM) recommended in 2005 that pregnant women should be educated on the value of cord blood stem cells early in pregnancy so an informed decision can be made about cord blood banking. In an effort to improve education to expecting parents, 17 states representing nearly two-thirds of all births in the U.S. have passed laws to implement the IOM guidance on cord blood education.

Umbilical cord blood is a rich and diverse source of newborn stem cells that can be collected without ethical concerns in a ten minute window immediately after birth. This population of stem cells has been used to treat nearly 80 diseases and is a preferred source of stem cells for clinical research in regenerative medicine because these cells have demonstrated embryonic-like capabilities to proliferate and develop into all of the major cell types in the body.

In parallel to the survey data collection, Cord Blood Registry invited physicians, nurses and other healthcare providers to provide input and perspective on the program. To date, nearly 7,000 healthcare providers have reviewed the on-line education program.

"It's great to finally have an up-to-date, easy-to-understand resource to direct my patients to as they are weighing their cord blood options," said Kelly Harkey, MD, MPH, an obstetrician and gynecologist based in California, which was one of the first states to focus on cord blood awareness. "Because educating patients about cord blood is encouraged in my state, it's nice that at the end of the program, patients are able to confirm they've been educated, which ensures my practice is compliant with state legislation."

The content of the program is divided into segments including a description of cord blood stem cells, the collection and storage process, the use of cord blood in current medical treatments, the latest information on new treatments in development, and the expecting patient's cord blood options. The content is accompanied by video segments and stories of how other families' cord blood banking decision impacted their lives. To use the on-line program, go to: http://www.cordblood.com/learn/.

About Cord Blood Registry

Cord Blood Registry(R) (CBR(R)) is the world's largest stem cell bank, focused on the collection, processing and storage of newborn stem cells from umbilical cord blood and ensuring their viability for medical use. CBR is the most recommended family cord blood bank by obstetricians and was the first family bank accredited by AABB (formerly the American Association of Blood Banks). The company has been profitable and cash flow positive from operations on a cumulative basis since 1999. CBR has processed and stored cord blood units for more than 300,000 newborns from around the world and has released more client cord blood units for specific therapeutic use than any other family cord blood bank. CBR is the leader in research and development efforts in collaboration with the world's leading clinical researchers focused on advancing regenerative medical therapies using a child's own cord blood stem cells. The company continues to enhance its industry-leading technical innovations for stem cell collection, processing and storage that optimize quality and cell yield. For more information, visit www.CordBlood.com.


'/>"/>
SOURCE Cord Blood Registry
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. First New York/New Jersey Health Care Report Card Released
2. Home Health Aide: Guidelines for Care Second Edition Released
3. Advaxis, Inc. phase I/II results of lovaxin C in cervical cancer study released
4. Poll Shows Voters Want Long Term Care Included in Presidential Candidates Healthcare Proposals, Released at 2007 National Long Term Care Symposium
5. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
6. Infection MonitorPro Version 1.1 Released during International Infection Prevention Week
7. Just-Released Cancer Report Provides New Ammunition for Farm Bill Reform Effort
8. New Research Released at AHA Confirms Itamars PAT Technology to Diagnose Early Cardiovascular Disease
9. Nurses Across Nation Host SiCKO House Parties to Urge Guaranteed Healthcare as DVD Released
10. Study Released at AHA Shows Survival to Hospital Discharge After Cardiac Arrest Doubles With Improved CPR and Impedance Threshold Device
11. A powerful literature and pathway mining system released to the public for free access
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is ... 11th, 2016 in honor of his birthday on February 10th. During this time, ... Trivedi is known by over 250,000 people from over 40 different countries as an ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by the ... dental technicians to be certified or obtain continuing education. To increase patient awareness ... In Your Mouth?” campaign to inform dentists and patients about the possible lack ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... women on Friday in recognition of National Wear Red Day. National Wear Red ... heart disease and stroke in women. Heart disease and stroke cause 1 in 3 ...
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... 2016 , ... US Sports Camps is proud to sponsor the Bay Area ... top non-profit leaders, ultimate organizations, and coaches from around the US. The theme for ... Program Director of Youth and Education, describes this year YUCC as “an important conversation ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016 ... the addition of the "Label-Free Detection ... Forecasts to 2020" report to their ... announced the addition of the "Label-Free ... Global Forecasts to 2020" report to ...
(Date:2/8/2016)... , Feb. 8, 2016  Unilife Corporation ("Unilife" or "Company") ... of injectable drug delivery systems, today announced that it will ... ended December 31, 2015 after market close on February 9, ... conference call to discuss these financial results.    ... --> About Unilife Corporation ...
(Date:2/8/2016)... 8, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced that the U.S. Food and Drug Administration ... (IND) application for SB-318, a single treatment strategy ... Type I (MPS I). The SB-318 IND application ... a Phase 1/2 clinical study (SB-318-1502) designed to ...
Breaking Medicine Technology: